Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.11.12 (PKG)
 2,515 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have used mammalian probes to clone genes encoding the catalytic (C) and type I regulatory (RI) components of the cAMP-dependent protein kinase in Drosophila. Both Drosophila gene products are very similar in amino acid sequence (RI, 71%; C, 82%) to their respective mammalian counterparts, implying homologous activity. A single Drosophila type I regulatory subunit gene is the source of at least three distinct transcripts originating from different promoters and spliced to a common body that would encode a full-length analog and two amino-terminally truncated variants of the mammalian RI protein. The RI locus also includes two intronic genes of unknown function. A single highly conserved catalytic subunit gene (DC0) was found that codes for a single polypeptide. It was used to isolate 11 further more distantly related apparent protein kinase genes. Two of these genes (DC1 and DC2) are sufficiently similar to DC0 in sequence (45% and 49% amino acid identity, respectively) that they could conceivably encode products of overlapping function. Two further genes are very similar in sequence to bovine cGMP-dependent protein kinase. The remaining putative gene products include amino acid sequence motifs characteristic of serine-threonine protein kinases but cannot, from the available data, be defined as homologous to specific protein kinases of other organisms.
 ...
PMID:Isolation and characterization of Drosophila cAMP-dependent protein kinase genes. 321 11

The clinical syndrome of heart failure is associated with both a resting vasoconstriction and reduced sensitivity to nitric oxide mediated vasodilatation, and this review will focus on the role of myosin light chain (MLC) phosphatase in the pathogenesis of the vascular abnormalities of heart failure. Nitric oxide mediates vasodilatation by an activation of guanylate cyclase and an increase in the production of cGMP, which leads to the activation of the type I cGMP-dependent protein kinase (PKGI). PKGI then activates a number of targets that produce smooth muscle relaxation including MLC phosphatase. MLC phosphatase is a holoenzyme consisting of three subunits; a 20 kD subunit of unknown function, an approximately 38-kD catalytic subunit and a myosin targeting subunit (MYPT1). Alternative splicing of a 31 bp 3 exon generates MYPT1 isoforms, which differ by a COOH-terminus leucine zipper (LZ). Further, PKGI-mediated activation of MLC phosphatase requires the expression of a LZ+ MYPT1. Congestive heart failure is associated with a decrease in LZ+ MYPT1 expression, which results in a decrease in the sensitivity to cGMP-mediated smooth muscle relaxation. Beyond their ability to reduce afterload, angiotensin converting enzyme (ACE) inhibitors have a number of beneficial effects that include maintaining the expression of the LZ+ MYPT1 isoform, thereby conserving normal sensitivity to cGMP-mediated vasodilatation, as well as differentially regulating genes associated with mitogen activated protein kinase (MAPK) signalling. ACE inhibition reduces circulating angiotensin II and thus limits the downstream activation of MAPK signalling pathways, possibly preventing the alteration of the vascular phenotype to preserve normal vascular function.
 ...
PMID:The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure. 1912 Jul